IL31RA and cancer: This effect of CSN5i-3 toward increasing presentation of peptides from these pathways, which is not unexpected given that CSN5i-3 promotes turnover of select CRL complexes (35, 36), speaks to the sensitivity and specificity of our methods and might have clinical applications in cancer patients with known mutations in these genes.